Severe 5-fluorouracil-related toxicity in a Japanese patient with dihydropyrimidine dehydrogenase deficiency

International Journal of Clinical Oncology

Volumn 4, Issue 1, 1999, Pages 54-56

  Inada, Takao ^a   Jotsuka, Toko ^a   Matsuda, Goro ^a   Kawakubo, Hirofumi ^a   Ogata, Yoshiro ^a   Kubota, Tetsuro ^b  

^a TOCHIGI CANCER CENTER   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Dihydropyrimidine dehydrogenase; Gastric cancer

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MITOMYCIN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CATABOLISM; CONTINUOUS INFUSION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MONONUCLEAR CELL; PRIORITY JOURNAL; STOMACH CANCER;

EID: 0033019019     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470050026     Document Type: Article

References (13)

1. Spears CP, Gustavsson BG, Mitchell MS, et al. (1984) Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res 44:4144-4150
2. Heggie GD, Sommadossi JP, Cross DS, et al. (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203-2206
3. Tuchman M, Stoeckler JS, Kianng DT, et al. (1985) Familial pyrimidinemia and pyrimidiuria associated with severe fluorouracil toxicity. New Engl J Med 313:245-249
4. Diasio RB, Beavers TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyridinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81:47-51
5. Kubota T, Sasano N, Abe O, et al. (1995) The Chemosensitivity Study Group for the Histoculture Drug-Response Assay. Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1:1537-1543
6. Harris BE, Song R, Soong SJ, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197-201
7. Ikenaka K, Shirasaka T, Kitano S, Fujii S (1979) Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann 70:353-359
8. Diasio RB, Beavers TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase. J Clin Invest 81:47-51
9. Etienne MC, Lagrange JL, Dassonville O, et al. (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12:2248-2253
10. Lu Z, Zhang R, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implications in 5-fluorouracil chemotherapy. Cancer Res 53:5433-5438
11. Hayashi K, Kidouchi K, Sumi S, et al. (1996) Possible prediction of adverse reactions to pyrimidine chemotherapy from urinary pyrimidine levels and a case of asymptomatic adult dihydropyrimidinuria. Clin Cancer Res 2:1937-1941
12. Beck A, Etienne MC, Cheradame S, et al. (1994) A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 30A:1517-1522
13. Johnson MR, Wang K, Tillmanns S, et al. (1997) Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Res 57:1660-1663